Beat Childhood Cancer Foundation

Beat Childhood Cancer Foundation Beat Childhood Cancer drives childhood cancer research helping kids TODAY, not a decade from now. Childhood cancer is not yet beaten.
(214)

Children are being diagnosed with cancer every day, and several childhood cancer types have heartbreakingly low survival rates. New treatment options (within reach for families), and a deeper understanding of how these tumors work are desperately needed. What we are doing is working. Here's how we work to beat childhood cancer:

Research Infrastructure
The Beat Childhood Cancer Research Consortium

(50+ children's hospitals) designs and rapidly enrolls kids on bold clinical trials, creating options. Precision Medicine
Understanding how and why each kids' tumor is working allows us to create personalized treatment plans, and discover novel treatments. Growing the Conversation
We amplify individual and broad stories from the childhood cancer community, and champion gold in September awareness to fund the work and clarify the need. We WILL beat childhood cancer.

When a child gets cancer, the system asks one question first: what kind of cancer is it?We think that's the wrong first ...
06/01/2026

When a child gets cancer, the system asks one question first: what kind of cancer is it?

We think that's the wrong first question.

Two children with the same diagnosis can have completely different cancers inside their bodies. What works for one might not work for the other. A cancer name on a chart does not tell you what is actually driving the disease.

Beat Childhood Cancer was built to change that.

We are an unprecedented allegiance of parents, doctors, researchers, and supporters. We sequence children's tumors to understand what is actually happening inside them. We treat each cancer by what it is, not just what it is called. We learn from every child, and what we learn helps the next family who walks in.

Everyday we create possibilities.
For Every Child. Everywhere.
beatcc.org/our-work

This month, you saw the allegiance at work.A family in San Diego that turned a cancer diagnosis into a foundation. A chi...
05/29/2026

This month, you saw the allegiance at work.

A family in San Diego that turned a cancer diagnosis into a foundation. A child diagnosed with a rare germ cell tumor who found hope in a treatment never considered for his cancer. The IN:Formation Project providing immediate and actionable tumor information. A molecular tumor board asking a question the standard system rarely asks: what is actually driving this specific tumor and what already exists that can fight it?

That last question is the one we're going deeper on in June.

Precision medicine. Stopping relapse. What it looks like when researchers are free to follow the child instead of just grants.

Stay with us.
beatcc.org/our-work

No two tumors are the same. And treatment shouldn’t be either.Through Beat Childhood Cancer’s IN:Formation Project, adva...
05/27/2026

No two tumors are the same. And treatment shouldn’t be either.

Through Beat Childhood Cancer’s IN:Formation Project, advanced DNA and RNA sequencing reveals what’s driving each child’s cancer so care can be tailored, not copied and pasted.

Instead of one-size-fits-all treatment, each tumor is analyzed, mapped, and matched to therapies designed for its specific mutations. Using this childhood cancer learning system and expert molecular tumor board, data becomes action helping doctors make more precise, informed decisions for every child.

Because when you treat cancer by its nature—not just its name—you open the door to smarter, more precise, and less toxic options.

Better data. Better decisions. Better outcomes. 💛
Learn more: beatcc.org/information

Children with cancer can’t wait for new treatments to start from scratch.The FDA is currently asking for public input on...
05/27/2026

Children with cancer can’t wait for new treatments to start from scratch.

The FDA is currently asking for public input on how already-approved drugs could be repurposed to address serious unmet medical needs — especially in rare and chronic diseases. Public comments are due June 11.

Families, doctors, researchers, and advocates can all help shape what comes next, because children with cancer can’t wait for the system to fix itself.

Learn more and submit comments through the FDA public docket: https://www.federalregister.gov/documents/2026/05/12/2026-09366/drug-repurposing-for-unmet-medical-needs-request-for-information

Read the FDA press release here: https://www.fda.gov/news-events/press-announcements/fda-advances-drug-repurposing-address-unmet-medical-needs

Nathan had been through three stem cell transplants. Standard treatments had been exhausted. His family came to the Beat...
05/23/2026

Nathan had been through three stem cell transplants. Standard treatments had been exhausted. His family came to the Beat Childhood Cancer Research Consortium looking for something, anything, that might help.

His tumor was sequenced through the IN:Formation Project. The results came back showing high sensitivity to DFMO, a drug BeatCC helped bring to FDA approval for neuroblastoma and is now being tested in sarcomas.

His tumor was not neuroblastoma. It was not sarcoma. It was a germ cell tumor. A cancer type never considered for DFMO.

But the sequencing found the connection. The allegiance followed it. Nathan is now in his longest remission. He is going to school. He feels well.

This is what child-informed treatment looks like in practice. Not treating cancer by its name, but following what the tumor actually reveals and meeting that child where they are.

The drugs that can help already exists. The question is whether someone is looking hard enough to find the match. That is what the BeatCC allegiance does, every day, for every child.

Learn more here: beatcc.org/information

This Is BIG: The BCC023 Trial using DFMO for Ewing Sarcoma and Osteosarcoma is NOW ENROLLING!!!!What This Is: DFMO (Eflo...
05/21/2026

This Is BIG: The BCC023 Trial using DFMO for Ewing Sarcoma and Osteosarcoma is NOW ENROLLING!!!!

What This Is: DFMO (Eflornithine) for Ewing Sarcoma and Osteosarcoma

What This Means: Ewing sarcoma and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation. There have been no real advancements to the standard of care in decades. By incorporating DFMO (eflornithine) as an additional therapy and/or maintenance therapy, our team of experts believe to observe improved event-free survival and overall survival.

Why This Matters: With little to no change to treatment protocol since the standards of care were developed, this trial provides an additional, less-toxic form of therapy for children battling these pediatric sarcomas. DFMO has been shown to successfully prevent relapse in neuroblastoma and laboratory research indicates the same results may be seen in sarcomas. This trial represents hope for countless children and families.

Anyone wishing to enroll immediately will have to travel to Penn State Health in Hershey until other sites begin to open. For enrollment information, please email: [email protected]

Research: Beat Childhood Cancer

For children diagnosed with DIPG, a brain tumor that forms in the brain stem, families hear the same thing: there is not...
05/19/2026

For children diagnosed with DIPG, a brain tumor that forms in the brain stem, families hear the same thing: there is nothing we can do. Radiation & steroids slow the tumor for roughly six months. From diagnosis to death, the timeline is typically about 12-18 months.

This is where the current system leaves DIPG families.

Beat Childhood Cancer believes that outcome is unacceptable.

Two clinical trial options now exist for children with DIPG through the Research Consortium. The PEACH Trial builds a personalized vaccine from each child's specific tumor using genomic sequencing. The DFMO/AMXT 1501 trial offers a low-toxicity oral and IV option that has shown effectiveness against DIPG in the lab. This combination of therapy can be administered largely at home without the brutal side effects of high-dose chemotherapy.

A third, highly anticipated clincial trial option for DIPG is currently in development.
This allegiance does not stand still. It keeps building options until every child has a chance.

If your child has been diagnosed with DIPG or another brain tumor, reach out. Options exist that didn't exist before.

In 2013, Parker was diagnosed with stage 4 neuroblastoma in San Diego. He went through years of treatment and participat...
05/15/2026

In 2013, Parker was diagnosed with stage 4 neuroblastoma in San Diego. He went through years of treatment and participated in a clinical trial using a drug called DFMO. It worked. Parker has been cancer free ever since.

His family didn't walk away from the fight when it was over. They started Team Parker for Life, a foundation that now funds the same kind of clinical research Parker participated in. The community around them rallied. The work continues.
That is what this allegiance makes possible.

Individual foundations don’t have to work in isolation to make a difference. Through collaboration, Team Parker For Life partnered with the Beat Childhood Cancer Research Consortium to strengthen the collective impact and help reach every child, everywhere.

What they help to fund moves the science forward for every child, everywhere, not just children in San Diego and not just children with neuroblastoma.
If your foundation is fighting for a child, you don't have to fight alone.

Visit beatcc.org to learn how we partner with foundations like yours.

Address

Delafield, WI

Website

Alerts

Be the first to know and let us send you an email when Beat Childhood Cancer Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Beat Childhood Cancer Foundation:

Shortcuts

Share

Category